Regeneron Pharmaceuticals (NSDQ:REGN) and Roche (OTCQX: RHHBY) are touting positive results from a Phase 2/3 study investigating the potential of REGEN-COV (casirivimab and imdevimab) antibody cocktail in hospitalized COVID-19 patients.
The study met its primary endpoint of reducing viral load within one week in seronegative patients needing low-flow or no supplemental oxygen.
REGEN-COV, known as Ronapreve outside of the U.S., led to a 36% reduced risk of death by day 29 in the overall treatment population.
“These new results, combined with the nearly 10,000-patient RECOVERY trial, further validate how REGEN-COV can change the course of illness for patients even after they are hospitalized with COVID-19,” said Dr. George D. Yancopoulos, president and chief scientific officer at Regeneron, in a statement.
Roche has partnered with Regeneron (NSDQ: REGN) to help manufacture and distribute REGN-COV2, which Regeneron first developed.
Roche’s chief medical officer, Dr. Levi Garraway, said the results indicate that the cocktail of casirivimab and imdevimab could “help to ease pressure on healthcare systems.”
The New England Journal of Medicine also published recent data on casirivimab and imdevimab in patients with severe COVID-19 infections.
The separate UK RECOVERY study came to similar conclusions, finding meaningful benefit for patients who received 2,400-mg or 8,000-mg doses of Ronapreve plus standard of care.